Pretreatment clinical and molecular characteristics and outcome according to WT1 mutation status in older and younger CN-AML patients
| Characteristic . | CN-AML patients 60 years or older . | CN-AML patients younger than 60 years* . | P . | ||||
|---|---|---|---|---|---|---|---|
| WT1mut (n = 16) . | WT1wt (n = 227) . | WT1mut (n = 24) . | WT1wt (n = 183) . | Patients 60 years or older: WT1mut vs WT1wt . | WT1mut: Patients 60 years or older vs patients younger than 60 years . | WT1wt: Patients 60 years or older vs patients younger than 60 years . | |
| Age, y | .30 | — | — | ||||
| Median | 67 | 68 | 43 | 45 | |||
| Range | 60-76 | 60-83 | 18-58 | 19-59 | |||
| Sex, no. (%) | .61 | .75 | .69 | ||||
| Male | 7 (44) | 117 (52) | 9 (38) | 90 (49) | |||
| Female | 9 (56) | 110 (48) | 15 (63) | 93 (51) | |||
| Race, no. (%) | .37 | 1.00 | .52 | ||||
| White | 16 (100) | 201 (90) | 23 (96) | 158 (88) | |||
| Nonwhite | 0 (0) | 22 (10) | 1 (4) | 22 (12) | |||
| Hemoglobin, g/dL | .01 | .37 | .48 | ||||
| Median | 8.2 | 9.4 | 9.3 | 9.4 | |||
| Range | 6.5-10.8 | 5.4-15.0 | 4.9-12.1 | 4.6-13.6 | |||
| Platelet count, ×109/L | .93 | .21 | .26 | ||||
| Median | 65 | 69 | 46 | 60 | |||
| Range | 18-254 | 4-850 | 7-235 | 8-466 | |||
| WBC, ×109/L | .03 | .64 | .18 | ||||
| Median | 57.0 | 24.7 | 49.3 | 23.8 | |||
| Range | 0.9-248.4 | 0.9-450.0 | 11.3-210.0 | 0.9-295.0 | |||
| Blood blasts, % | .03 | .79 | .002 | ||||
| Median | 68 | 41 | 62 | 58 | |||
| Range | 5-96 | 0-99 | 10-93 | 0-97 | |||
| Bone marrow blasts, % | .09 | .18 | .66 | ||||
| Median | 80 | 66 | 67 | 65 | |||
| Range | 27-97 | 7-97 | 30-93 | 10-99 | |||
| FAB, no. (%)† | — | — | — | ||||
| M0 | 0 (0) | 4 (3) | 0 (0) | 5 (4) | |||
| M1 | 4 (33) | 28 (20) | 5 (24) | 39 (29) | |||
| M2 | 2 (17) | 44 (32) | 9 (43) | 41 (30) | |||
| M4 | 3 (25) | 34 (24) | 6 (29) | 33 (24) | |||
| M5 | 3 (25) | 24 (17) | 0 (0) | 16 (12) | |||
| M6 | 0 (0) | 5 (4) | 1 (5) | 0 (0) | |||
| Extramedullary involvement, no. (%) | 3 (19) | 50 (23) | 7 (29) | 54 (30) | 1.00 | .71 | .11‡ |
| FLT3-ITD, no. (%) | < .001 | .33 | .33 | ||||
| Present | 12 (75) | 66 (29) | 14 (58) | 62 (34) | |||
| Absent | 4 (25) | 161 (71) | 10 (42) | 121 (66) | |||
| FLT3-TKD, no. (%) | 1.00 | .64 | .74 | ||||
| Present | 1 (6) | 23 (10) | 3 (13) | 16 (9) | |||
| Absent | 15 (94) | 204 (90) | 21 (88) | 163 (91) | |||
| NPM1, no. (%) | .80 | .73 | .13 | ||||
| Mutated | 10 (63) | 130 (57) | 17 (71) | 119 (65) | |||
| Wild-type | 6 (38) | 97 (43) | 7 (29) | 64 (35) | |||
| CEBPA, no. (%) | 1.00 | .44 | .20 | ||||
| Mutated | 2 (13) | 27 (12) | 6 (25) | 30 (16) | |||
| Wild-type | 14 (88) | 200 (88) | 18 (75) | 152 (84) | |||
| ERG expression, no. (%)§ | .21 | — | — | ||||
| High | 8 (73) | 71 (48) | 13 (68) | 42 (34) | |||
| Low | 3 (27) | 76 (52) | 6 (32) | 82 (66) | |||
| BAALC expression, no. (%)‖ | .21 | 1.00 | .55 | ||||
| High | 8 (73) | 71 (48) | 17 (77) | 59 (44) | |||
| Low | 3 (27) | 76 (52) | 5 (23) | 75 (56) | |||
| CR, no. (%) | 8 (50) | 158 (70) | 18 (75) | 154 (84) | .16 | .18 | < .001 |
| Disease-free survival | .59 | .66 | < .001 | ||||
| Median, y | 0.7 | 0.9 | 0.6 | 3.1 | |||
| Disease-free at 3 y (95% CI), % | 13 (1-42) | 17 (12-23) | 17 (4-37) | 50 (42-58) | |||
| Overall survival | .08 | .68 | < .001 | ||||
| Median, y | 0.7 | 1.2 | 0.8 | 4.6 | |||
| Alive at 3 y (95% CI), % | 13 (2-33) | 20 (15-26) | 13 (3-29) | 56 (49-63) | |||
| Characteristic . | CN-AML patients 60 years or older . | CN-AML patients younger than 60 years* . | P . | ||||
|---|---|---|---|---|---|---|---|
| WT1mut (n = 16) . | WT1wt (n = 227) . | WT1mut (n = 24) . | WT1wt (n = 183) . | Patients 60 years or older: WT1mut vs WT1wt . | WT1mut: Patients 60 years or older vs patients younger than 60 years . | WT1wt: Patients 60 years or older vs patients younger than 60 years . | |
| Age, y | .30 | — | — | ||||
| Median | 67 | 68 | 43 | 45 | |||
| Range | 60-76 | 60-83 | 18-58 | 19-59 | |||
| Sex, no. (%) | .61 | .75 | .69 | ||||
| Male | 7 (44) | 117 (52) | 9 (38) | 90 (49) | |||
| Female | 9 (56) | 110 (48) | 15 (63) | 93 (51) | |||
| Race, no. (%) | .37 | 1.00 | .52 | ||||
| White | 16 (100) | 201 (90) | 23 (96) | 158 (88) | |||
| Nonwhite | 0 (0) | 22 (10) | 1 (4) | 22 (12) | |||
| Hemoglobin, g/dL | .01 | .37 | .48 | ||||
| Median | 8.2 | 9.4 | 9.3 | 9.4 | |||
| Range | 6.5-10.8 | 5.4-15.0 | 4.9-12.1 | 4.6-13.6 | |||
| Platelet count, ×109/L | .93 | .21 | .26 | ||||
| Median | 65 | 69 | 46 | 60 | |||
| Range | 18-254 | 4-850 | 7-235 | 8-466 | |||
| WBC, ×109/L | .03 | .64 | .18 | ||||
| Median | 57.0 | 24.7 | 49.3 | 23.8 | |||
| Range | 0.9-248.4 | 0.9-450.0 | 11.3-210.0 | 0.9-295.0 | |||
| Blood blasts, % | .03 | .79 | .002 | ||||
| Median | 68 | 41 | 62 | 58 | |||
| Range | 5-96 | 0-99 | 10-93 | 0-97 | |||
| Bone marrow blasts, % | .09 | .18 | .66 | ||||
| Median | 80 | 66 | 67 | 65 | |||
| Range | 27-97 | 7-97 | 30-93 | 10-99 | |||
| FAB, no. (%)† | — | — | — | ||||
| M0 | 0 (0) | 4 (3) | 0 (0) | 5 (4) | |||
| M1 | 4 (33) | 28 (20) | 5 (24) | 39 (29) | |||
| M2 | 2 (17) | 44 (32) | 9 (43) | 41 (30) | |||
| M4 | 3 (25) | 34 (24) | 6 (29) | 33 (24) | |||
| M5 | 3 (25) | 24 (17) | 0 (0) | 16 (12) | |||
| M6 | 0 (0) | 5 (4) | 1 (5) | 0 (0) | |||
| Extramedullary involvement, no. (%) | 3 (19) | 50 (23) | 7 (29) | 54 (30) | 1.00 | .71 | .11‡ |
| FLT3-ITD, no. (%) | < .001 | .33 | .33 | ||||
| Present | 12 (75) | 66 (29) | 14 (58) | 62 (34) | |||
| Absent | 4 (25) | 161 (71) | 10 (42) | 121 (66) | |||
| FLT3-TKD, no. (%) | 1.00 | .64 | .74 | ||||
| Present | 1 (6) | 23 (10) | 3 (13) | 16 (9) | |||
| Absent | 15 (94) | 204 (90) | 21 (88) | 163 (91) | |||
| NPM1, no. (%) | .80 | .73 | .13 | ||||
| Mutated | 10 (63) | 130 (57) | 17 (71) | 119 (65) | |||
| Wild-type | 6 (38) | 97 (43) | 7 (29) | 64 (35) | |||
| CEBPA, no. (%) | 1.00 | .44 | .20 | ||||
| Mutated | 2 (13) | 27 (12) | 6 (25) | 30 (16) | |||
| Wild-type | 14 (88) | 200 (88) | 18 (75) | 152 (84) | |||
| ERG expression, no. (%)§ | .21 | — | — | ||||
| High | 8 (73) | 71 (48) | 13 (68) | 42 (34) | |||
| Low | 3 (27) | 76 (52) | 6 (32) | 82 (66) | |||
| BAALC expression, no. (%)‖ | .21 | 1.00 | .55 | ||||
| High | 8 (73) | 71 (48) | 17 (77) | 59 (44) | |||
| Low | 3 (27) | 76 (52) | 5 (23) | 75 (56) | |||
| CR, no. (%) | 8 (50) | 158 (70) | 18 (75) | 154 (84) | .16 | .18 | < .001 |
| Disease-free survival | .59 | .66 | < .001 | ||||
| Median, y | 0.7 | 0.9 | 0.6 | 3.1 | |||
| Disease-free at 3 y (95% CI), % | 13 (1-42) | 17 (12-23) | 17 (4-37) | 50 (42-58) | |||
| Overall survival | .08 | .68 | < .001 | ||||
| Median, y | 0.7 | 1.2 | 0.8 | 4.6 | |||
| Alive at 3 y (95% CI), % | 13 (2-33) | 20 (15-26) | 13 (3-29) | 56 (49-63) | |||
— indicates not applicable; WBC, white blood cell count; FAB, French-American-British classification; and CI, confidence interval.
Data on 194 of these patients have been previously published.2
FAB are centrally reviewed.
Trend mainly resulting from less frequent lymphadenopathy in WT1wt patients 60 years of age or older compared with WT1wt patients less than 60 years (P = .02).
For patients in CALGB 9621, the cutoff point is the same as in Marcucci et al.15 For patients in all other protocols, the median ERG expression value was used for the cutoff point.
The median BAALC expression value was used for the cutoff point.